Turnstone Biologics (TSBX) Stock Forecast, Price Target & Predictions
TSBX Stock Forecast
Turnstone Biologics stock forecast is as follows: an average price target of $0.50 (represents a 10.60% upside from TSBX’s last price of $0.45) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TSBX Price Target
The average price target for Turnstone Biologics (TSBX) is $0.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $0.50 to $0.50. This represents a potential 10.60% upside from TSBX's last price of $0.45.
TSBX Analyst Ratings
According to 2 Wall Street analysts, Turnstone Biologics's rating consensus is 'Buy'. The analyst rating breakdown for TSBX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Turnstone Biologics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Charlie Yang | Bank of America Securities | $0.50 | $0.46 | 8.23% | 10.60% |
The latest Turnstone Biologics stock forecast, released on Oct 14, 2024 by Charlie Yang from Bank of America Securities, set a price target of $0.50, which represents a 8.23% increase from the stock price at the time of the forecast ($0.46), and a 10.60% increase from TSBX last price ($0.45).
Turnstone Biologics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $0.50 | $0.50 |
| Last Closing Price | $0.45 | $0.45 | $0.45 |
| Upside/Downside | -100.00% | 10.60% | 10.60% |
In the current month, the average price target of Turnstone Biologics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Turnstone Biologics's last price of $0.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Bank of America Securities | Reduce | Downgrade | |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Turnstone Biologics's last stock rating was published by Bank of America Securities on Oct 14, 2024. The company Downgrade its TSBX rating from "null" to "Reduce".
Turnstone Biologics Financial Forecast
Turnstone Biologics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Turnstone Biologics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TSBX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Turnstone Biologics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict TSBX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Turnstone Biologics's previous annual EBITDA (undefined) of $NaN.
Turnstone Biologics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-18.66M | $-18.66M | $-18.55M | $-18.43M | $-19.58M | $-19.81M | $-19.35M |
| High Forecast | $-18.66M | $-18.66M | $-18.55M | $-18.43M | $-19.35M | $-19.81M | $-19.35M |
| Low Forecast | $-18.66M | $-18.66M | $-18.55M | $-18.43M | $-19.81M | $-19.81M | $-19.35M |
| Surprise % | - | - | - | - | - | - | - |
Turnstone Biologics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TSBX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Turnstone Biologics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Turnstone Biologics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TSBX last annual SG&A of $NaN (undefined).
Turnstone Biologics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.81 | $-0.81 | $-0.81 | $-0.80 | $-0.85 | $-0.86 | $-0.84 |
| High Forecast | $-0.81 | $-0.81 | $-0.81 | $-0.80 | $-0.84 | $-0.86 | $-0.84 |
| Low Forecast | $-0.81 | $-0.81 | $-0.81 | $-0.80 | $-0.86 | $-0.86 | $-0.84 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Turnstone Biologics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TSBX previous annual EPS of $NaN (undefined).